Trabeculectomy

MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE

Retrieved on: 
수요일, 5월 1, 2024
Glaucoma surgery, Sale, University, Moran Eye Center, Lecture, TGT, Refractive surgery, Hospital, Safety, Research, Cataract, Paratriathlon, IOP, Manchester Royal Eye Hospital, NCT, Biomaterial, ASCRS, Intraocular pressure, Patient, Society, Physician, ICGS, EGS, Glaucoma, Trabeculectomy, Moorfields Eye Hospital, ARVO, Medical device

Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.

Key Points: 
  • Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.
  • The Calibreye shunt is designed to deliver an adjustable solution to control IOP in patients requiring low IOP.
  • While these devices have demonstrated an improvement in complication rates, achieving the IOP reductions necessary for these glaucoma patients remains challenging.
  • The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is for investigational use only and is not for sale in the U.S. or outside the U.S.

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Retrieved on: 
월요일, 11월 27, 2023
AAO, LCD, MAC, Retina, Effective date, Macs, American Academy, CPC, Medicare, Patient, Safety, IRIX, Trabeculectomy, Glaucoma

MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC).

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC).
  • During the last few days, the five Medicare Administrative Contractors (MACs) that issued the new LCDs have all corrected errors in criteria for coverage of CPC resulting in significantly broader patient qualification in the jurisdictions of these MACs.
  • Specifically, the list of patient characteristics used in the criteria, which had been separated by the word “AND,” are corrected to be separated by the word “OR” and read as follows:
    “4.
  • Cyclophotocoagulation will be considered medically reasonable and necessary for patients with refractory glaucoma when:
    a.

Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma

Retrieved on: 
목요일, 7월 28, 2022
Association, Canadian Securities Administrators, Eye, Trabeculectomy, Lens (anatomy), Fear, Trust, U.S. Securities and Exchange Commission, Instagram, Twitter, Bausch & Lomb, CEO, NYSE, Severe cognitive impairment, COVID-19, News, Glaucoma, Facebook, Technology, Patient, LinkedIn, Pressure, MIMS, Prevalence, TEL, Medical device, Pharmaceutical industry

VAUGHAN, ON and TEL AVIV, Israel, July 28, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Sanoculis, an Israeli ophthalmic medical device start-up company, today announced they have entered into strategic agreements designed to address unmet needs in glaucoma. The companies have entered into an exclusive European distribution agreement for Sanoculis' Minimally Invasive Micro Sclerostomy ("MIMS®"), an innovative minimally invasive surgical procedure for the treatment of glaucoma. Additionally, Bausch + Lomb has made an equity investment in Sanoculis as part of a Series C round of funding.

Key Points: 
  • VAUGHAN, ON and TEL AVIV, Israel, July 28, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Sanoculis, an Israeli ophthalmic medical device start-up company, today announced they have entered into strategic agreements designed to address unmet needs in glaucoma.
  • Additionally, Bausch + Lomb has made an equity investment in Sanoculisas part of a Series C round of funding.
  • "As a global eye health leader with a fully integrated eye care portfolio, Bausch + Lomb remains committed to holistically addressing eye health problems, particularly in continuing areas of unmet need like glaucoma."
  • "Both the distribution agreement and investment are a significant milestone for Sanoculis, because they demonstrate the strong trust Bausch + Lomb has in our technology.

Orbis International Launches Virtual Flying Eye Hospital Program in Ethiopia

Retrieved on: 
화요일, 5월 10, 2022
Organic, Glaucoma, Population, Volunteering, Cataract, University, Visual impairment, Orbis International, Trabeculectomy, Time, Government, Eye bank, Drainage, Hospital, Knowledge, Ophthalmology, Health, Aircraft, Phacoemulsification, MD-10, CEO, Optometry, Candid (organization), Severe cognitive impairment, Trachoma, Medicine, Orbis

NEW YORK, May 10, 2022 /PRNewswire/ -- Eye care nonprofit Orbis announces the launch of a new virtual Flying Eye Hospital program that will provide tailored training to eye care professionals in Ethiopia on treating glaucoma and cataract, leading causes of blindness and visual impairment in the country. With a population of roughly 120 million, Ethiopia is in desperate need of more qualified eye care professionals. However, only a handful of academic institutions offer training opportunities for a small number of ophthalmology residents each year. The lack of eye health specialists has translated to challenges in providing equitable eye care services in the country, including effective treatments to reduce visual impairment caused by glaucoma and cataract.

Key Points: 
  • NEW YORK, May 10, 2022 /PRNewswire/ --Eye care nonprofit Orbis announces the launch of a new virtual Flying Eye Hospital program that will provide tailored training to eye care professionals in Ethiopia on treating glaucoma and cataract, leading causes of blindness and visual impairment in the country.
  • Two courses will be offered during the ten-week virtual Flying Eye Hospital program.
  • In 2020, Orbis reimagined in-person Flying Eye Hospital trainings as virtual ones to ensure that eye care teams could still access critical training safely during the pandemic.
  • Orbis reached nine countries in 2020 and 34 countries in 2021 through virtual Flying Eye Hospital projects.

New Virtual Training Takes on Vision Loss Due to Glaucoma

Retrieved on: 
화요일, 5월 3, 2022
Organic, FedEx Express, Glaucoma, Volunteering, Brain, Maintenance, University, Visual impairment, NEW, Retinopathy, Orbis International, NYSE, Learning curve, Trabeculectomy, Safety, Eye, Premature, Community, FDX, FedEx, Patient, Review, Government, Acquisition, Hospital, Knowledge, Pressure, Business operations, Severe cognitive impairment, Ophthalmology, Health, Aircraft, MD-10, Technology, Solution, CEO, Candid (organization), Transport, Medicine, Orbis

NEW YORK, May 3, 2022 /PRNewswire/ -- Orbis International, with generous support from FedEx, launched a new virtual Flying Eye Hospital project that will train eye care professionals across Vietnam on ways to prevent the worsening of vision loss due to glaucoma, a leading cause of blindness and visual impairment. The number of glaucoma cases in Vietnam is increasing, especially among the younger population, as the country continues to face shortages of skilled eye care professionals and limited access to quality eye care, particularly in rural areas.  

Key Points: 
  • Glaucoma is the result of damage to the nerve connecting the eye to the brain caused by pressure from fluid buildup in the eye.
  • In 2020, Orbis reimagined in-person Flying Eye Hospital trainings as virtual ones to ensure that eye care teams could still access critical training safely during the pandemic.
  • Orbis reached nine countries in 2020 and 34 countries in 2021 through virtual Flying Eye Hospital projects.
  • FedEx has played an indispensable role in helping Orbis achieve its mission by providing aircraft parts, maintenance and pilot training.

Verana Health Unveils Annual Ophthalmic Industry Report that Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Period

Retrieved on: 
금요일, 4월 22, 2022
Society, Trabeculectomy, ASCRS, Annual general meeting, Research, Endophthalmitis, Health, Medicine, Patient, Stanford University School of Medicine, SAN, EHR, American Society of Cataract and Refractive Surgery, Choroidal neovascularization, IRIS, Game Industry Report Magazine, Cataract, ICD, Perioperative, Refractive surgery, American Academy, Disease, Natural language processing, Machine Intelligence Research Institute, NLP, Ophthalmology

SAN FRANCISCO, April 22, 2022 /PRNewswire/ -- Verana Health®—a digital health data company elevating quality in real-world data—today announced the release of its American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Industry Report for 2021 at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26 in Washington, D.C. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained in the IRIS Registry, powered by Verana Health's VeraQ™ population health data engine.

Key Points: 
  • The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained in the IRIS Registry, powered by Verana Health's VeraQ population health data engine.
  • The IRIS Registry is the nation's first and the world's largest electronic health record-based registry on comprehensive eye disease and conditions.
  • The IRIS Registry Report shows a more than 80% increase in glaucoma surgeries over an 8-year period from 2013-2021*.
  • The report also outlines Verana Health's curation of research-ready cohorts to better understand disease and treatment impacts for ocular surface health.

ELT Sight Announces Scientific Advisory Board

Retrieved on: 
수요일, 1월 15, 2020
Optical, Health, Surgery, Clinical trials, Medicine, Eye surgery, Medical specialties, Clinical medicine, Excimer laser trabeculostomy, Trabectome, ELT, Glaucoma surgery, Trabeculectomy, Glaucoma, Cataract surgery, Cataract

ELT Sight, Inc. today announced the creation of their Scientific Advisory Board.

Key Points: 
  • ELT Sight, Inc. today announced the creation of their Scientific Advisory Board.
  • ELT Sight recently announced that in the largest published study to date on ELT, the ExTra ELT procedure plus cataract surgery was superior to ab interno trabeculectomy with the Trabectome plus cataract surgery in survival analysis.
  • ELT Sight, Inc., based in Los Angeles and Munich, Germany, is focused on effective, safe and longer-term microinvasive glaucoma surgery with its ExTra excimer laser trabeculostomy (ELT) device.
  • ELT Sight plans to begin clinical studies of ExTra ELT in the United States in 2020.

Study Shows Superior Success Rate for ExTra ELT Compared With Trabectome in Patients With Glaucoma Plus Cataract Surgery

Retrieved on: 
화요일, 12월 3, 2019
Optical, Health, Surgery, Clinical trials, Medicine, Eye surgery, Medical specialties, Clinical medicine, Trabectome, Excimer laser trabeculostomy, Glaucoma, Cataract surgery, Trabeculectomy, Cataract, Minimally invasive glaucoma surgery, Phacolytic glaucoma

ELT Sight, Inc. today announced that in the largest published study to date on excimer laser trabeculostomy (ELT), the ExTra ELT procedure plus cataract surgery was superior to ab interno trabeculectomy with the Trabectome plus cataract surgery.

Key Points: 
  • ELT Sight, Inc. today announced that in the largest published study to date on excimer laser trabeculostomy (ELT), the ExTra ELT procedure plus cataract surgery was superior to ab interno trabeculectomy with the Trabectome plus cataract surgery.
  • Patients in the retrospective, non-randomized, comparative single surgery center study (Hamburg, Germany) underwent one of three procedures: combined ELT plus cataract surgery, trabeculectomy with the Trabectome device plus cataract surgery, or cataract surgery alone.
  • At 1-year postoperative, ELT plus cataract surgery significantly reduced intraocular pressure (IOP) and medication use, which are two major and challenging treatment goals for cataract patients with glaucoma.
  • Additionally, ExTra ELT plus cataract surgery was significantly superior in Kaplan-Meier survival analysis at 1 year compared to the other two techniques.

Ivantis Announces Groundbreaking 3 Year Results from FDA Clinical Trial; First Device in Minimally Invasive Glaucoma Surgical (MIGS) Category to Demonstrate Significant Long Term Reduction of Severe Major Surgeries for Glaucoma Patients

Retrieved on: 
목요일, 5월 2, 2019
Medicine, Medical specialties, Clinical medicine, Eye surgery, Blindness, RTT, Glaucoma, Trabeculectomy, Ophthalmology, Cataract surgery, Cataract, Minimally invasive glaucoma surgery

The study included patients with mild-to-moderate glaucoma undergoing cataract surgery, and had a 2:1 randomization either to Hydrus Microstent plus cataract surgery, or cataract surgery alone.

Key Points: 
  • The study included patients with mild-to-moderate glaucoma undergoing cataract surgery, and had a 2:1 randomization either to Hydrus Microstent plus cataract surgery, or cataract surgery alone.
  • Invasive procedures, such as trabeculectomy, are life changing events for our patients, and often have devastating complications and adverse quality of life ramifications.
  • Ivantis, Inc. is a privately held company established in 2007 to design, develop and commercialize new technologies to treat eye disease.
  • The company is headquartered in Irvine, Calif.
    Ivantis and Hydrus are registered trademarks of Ivantis, Inc. All rights reserved 2019.

International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery

Retrieved on: 
화요일, 3월 12, 2019
Health, Clinical trials, Medical devices, Optical, Pharmaceutical, Medicine, Medical specialties, Eye surgery, Clinical medicine, Glaucoma, Minimally invasive glaucoma surgery, Trabeculectomy, MIGS, Glaukos

Thirty-eight percent of eyes had undergone prior trabeculectomy and/or glaucoma laser procedures and 68% were on at least two preoperative glaucoma medications.

Key Points: 
  • Thirty-eight percent of eyes had undergone prior trabeculectomy and/or glaucoma laser procedures and 68% were on at least two preoperative glaucoma medications.
  • Glaukos is the pioneer of Micro-Invasive Glaucoma Surgery, or MIGS.
  • Inserted through a small corneal incision made during cataract surgery, the iStent is designed to reduce IOP by restoring the natural physiological outflow of aqueous humor.
  • The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.